Public Policy Resources

The U.S. Food and Drug Administration's (FDA's) typically follows a standard review process to evaluate a drug’s safety and efficacy. However, drug therapies that address unmet medical needs, treat serious or life-threatening conditions, or show a significant advantage over current therapies may be eligible for one or more of FDA’s four Expedited Review Programs. This factsheet describes those programs.  

A significant portion of the U.S. Food and Drug Administration's (FDA's) operating budget comes from user fees paid by industry.  The authority to collect these fees expires every five years and must be renewed.  This factsheet describes the program.  

In response to ClinicalTrials.gov's request for information to guide their modernization process, ACS CAN, along with 14 other organizations, submitted extensive comments.  The suggestions were derived from multi-stakeholder collaborations underway over the past year and reflect consensus ideas a

In response to a request from FDA, ACS CAN has provided recommendations for areas of focus for the Office of Minority Health and Health Equity (OMHHE).  Recommendations include assessing the applicability of drug "snapshot" data, evaluating the appropriateness of aggregating racial groups for ana

In response to a request from Reps. Upton and DeGette for ideas to include in Cures 2.0 legislation, ACS CAN and six other organization urged the representatives to consider the recommendations for overcoming barriers to clinical trial participation published as part of a recent landscape report.

In October 2019, CMS revised its earlier National Coverage Decision (NCD) regarding Next-Generation Sequencing (NGS).  CMS recongized that its previous policy had unintended consequences with respect to germline testing and modified its policy.  While ACS CAN supports this policy change, several

The National Program of Cancer Registries (NPCR) at the Centers for Disease Control and Prevention (CDC) provides technical, operational, and financial support to almost all state cancer registries to help ensure data collected are representative of the U.S. population.

Clinical trials are the key step in advancing potential new cancer treatments from the research setting to the cancer care clinic, and patient participation in trials is crucial to this success.

ACS CAN responded to the reopening of the Centers for Medicare and Medicaid Services (CMS) coverage decision for NGS testing panels.